FDA approves Tezspire for chronic rhinosinusitis with nasal polyps
The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adult and pediatric patients ...
Oct 28, 2025
0
0




